Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally_老虎社区_美港股上老虎

Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally

benzinga2021-06-16

Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares. What Happened...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

CkSck
·2021-06-17
Wow
回复
点赞
举报
HuiHong
·2021-06-16
nice
回复
点赞
举报
enyj
·2021-06-16
geo
回复
点赞
举报
Jackie_Woo
·2021-06-16
Good
回复
点赞
举报
收起
- charlito:
  good
  2021-06-16
  回复
  举报
9199ni
·2021-06-16
good
回复
2
举报
9199ni
·2021-06-16
nice
回复
1
举报
GME1mBy2022
·2021-06-16
PLZ REPLY TO COMMENT TO WIN 9999 TRILLION DOLLARS THX
回复
2
举报
收起
- boonchek:
  Comment back and win too! Lol
  2021-06-16
  回复
  举报
Simba2021
·2021-06-16
👍👍
回复
3
举报
Vintorez
·2021-06-16
O.o
回复
2
举报
TripleWin
·2021-06-16
Bad news
回复
4
举报
收起
- Veldora:
  How bad is this news? Nothing much change for the company
  2021-06-16
  回复
  举报
- AurulentL:
  Comment Pls
  2021-06-16
  回复
  举报
- Veldora回复AurulentL:
  Commented
  2021-06-16
  回复
  举报
HyperBaka
·2021-06-16
A
回复
1
举报
收起
- megastonks:
  nice
  2021-06-16
  回复
  举报
Desmond669
·2021-06-16
Good read
回复
2
举报
收起
- JZT:
  👍
  2021-06-16
  回复
  举报
megastonks
·2021-06-16
Like
回复
3
举报
收起
- JZT:
  👍
  2021-06-16
  回复
  举报
Raymond杨
·2021-06-16
Nice kindly comment thank you
回复
3
举报
收起
- JZT:
  👍
  2021-06-16
  回复
  举报
bkohh
·2021-06-16
like
回复
1
举报
收起
- kenta:
  wow
  2021-06-16
  回复
  举报
Rayechia
·2021-06-16
Tell me your opinion about this news...
回复
1
举报
收起
- bkohh:
  ok
  2021-06-16
  回复
  举报
CollinNgu
·2021-06-16
Hmmm
回复
1
举报
收起
- QQ23:
  Yup
  2021-06-16
  回复
  举报
- Princessleo:
  Yup
  2021-06-16
  回复
  举报
- Rayechia:
  Ok
  2021-06-16
  回复
  举报
查看更多 1 条评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1150256789?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-06-16 16:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150256789","market":"us","top_or_hot":-1,"title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","media":"benzinga","content":"<html><body><div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">网页链接</a>\n</div>\n</body></html>","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","article_id":"1150256789","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","pubTimestamp":1623833619,"columns":[],"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Orphazyme的主要投资者Sunstone在散户投资者推动的反弹后减持了股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORPH":0.9},"content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","kind":"news","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":161565775,"gmtCreate":1623935532497,"gmtModify":1634025678741,"author":{"id":"3581591880603790","authorId":"3581591880603790","name":"CkSck","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581591880603790","authorIdStr":"3581591880603790"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161565775","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169430424,"gmtCreate":1623846637768,"gmtModify":1634027195819,"author":{"id":"3556146747015641","authorId":"3556146747015641","name":"HuiHong","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3556146747015641","authorIdStr":"3556146747015641"},"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169430424","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169593843,"gmtCreate":1623841457482,"gmtModify":1634027281196,"author":{"id":"3586783123137653","authorId":"3586783123137653","name":"enyj","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586783123137653","authorIdStr":"3586783123137653"},"htmlText":"geo","listText":"geo","text":"geo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169593843","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169210097,"gmtCreate":1623837218419,"gmtModify":1634027340180,"author":{"id":"3576668642994061","authorId":"3576668642994061","name":"Jackie_Woo","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3576668642994061","authorIdStr":"3576668642994061"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/169210097","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4808641,"gmtCreate":1623841153221,"gmtModify":1635316552264,"authorId":3581727570212837,"author":{"id":3581727570212837,"idStr":"3581727570212837","authorId":3581727570212837,"name":"charlito","avatar":"https://static.tigerbbs.com/187f09a2c9b9e341d7b9423366682194","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":169210097,"type":1,"supId":0,"prevId":0,"content":"<u>good</u>","text":"<u>good</u>","html":"<u>good</u>"}],"langContent":"EN"},{"id":169236424,"gmtCreate":1623837013768,"gmtModify":1634027342796,"author":{"id":"3583228238671976","authorId":"3583228238671976","name":"9199ni","avatar":"https://static.tigerbbs.com/8890ad4144b00eff4f6d77481bf1f859","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3583228238671976","authorIdStr":"3583228238671976"},"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169236424","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169236914,"gmtCreate":1623836990438,"gmtModify":1634027343490,"author":{"id":"3583228238671976","authorId":"3583228238671976","name":"9199ni","avatar":"https://static.tigerbbs.com/8890ad4144b00eff4f6d77481bf1f859","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3583228238671976","authorIdStr":"3583228238671976"},"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169236914","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169679307,"gmtCreate":1623835180909,"gmtModify":1631884269229,"author":{"id":"3575188872322547","authorId":"3575188872322547","name":"GME1mBy2022","avatar":"https://static.tigerbbs.com/9b0ea54290166f528c67da36f0e46841","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575188872322547","authorIdStr":"3575188872322547"},"htmlText":"PLZ REPLY TO COMMENT TO WIN 9999 TRILLION DOLLARS THX&nbsp;","listText":"PLZ REPLY TO COMMENT TO WIN 9999 TRILLION DOLLARS THX&nbsp;","text":"PLZ REPLY TO COMMENT TO WIN 9999 TRILLION DOLLARS THX","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/169679307","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4807277,"gmtCreate":1623835505044,"gmtModify":1635316664444,"authorId":3582036219515358,"author":{"id":3582036219515358,"idStr":"3582036219515358","authorId":3582036219515358,"name":"boonchek","avatar":"https://static.tigerbbs.com/c615abbfde8feafcbdd8e88179f1e152","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":169679307,"type":1,"supId":0,"prevId":0,"content":"Comment back and win too! Lol","text":"Comment back and win too! Lol","html":"Comment back and win too! Lol"}],"langContent":"EN"},{"id":169647016,"gmtCreate":1623835070435,"gmtModify":1634027368840,"author":{"id":"3579251645799474","authorId":"3579251645799474","name":"Simba2021","avatar":"https://static.tigerbbs.com/f0d951f7cf49cd1f3cdd6f0d1a470ca5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579251645799474","authorIdStr":"3579251645799474"},"htmlText":"👍👍","listText":"👍👍","text":"👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169647016","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169659949,"gmtCreate":1623834170981,"gmtModify":1634027379719,"author":{"id":"3584264973093876","authorId":"3584264973093876","name":"Vintorez","avatar":"https://static.tigerbbs.com/b8c87d9b4d20796c59a4630f150f1d35","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3584264973093876","authorIdStr":"3584264973093876"},"htmlText":"O.o","listText":"O.o","text":"O.o","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169659949","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169624850,"gmtCreate":1623834031070,"gmtModify":1634027381575,"author":{"id":"3577489740102994","authorId":"3577489740102994","name":"TripleWin","avatar":"https://static.tigerbbs.com/36f6d7690fd546416bd6f74b156c218f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577489740102994","authorIdStr":"3577489740102994"},"htmlText":"Bad news","listText":"Bad news","text":"Bad news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/169624850","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806878,"gmtCreate":1623834133347,"gmtModify":1635316698899,"authorId":3580473686930895,"author":{"id":3580473686930895,"idStr":"3580473686930895","authorId":3580473686930895,"name":"Veldora","avatar":"https://static.tigerbbs.com/2c60768e017f3418615cd7dea3a291ec","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":169624850,"type":1,"supId":0,"prevId":0,"content":"How bad is this news? Nothing much change for the company","text":"How bad is this news? Nothing much change for the company","html":"How bad is this news? Nothing much change for the company"},{"id":4806886,"gmtCreate":1623834151149,"gmtModify":1635316698380,"authorId":3581585314538349,"author":{"id":3581585314538349,"idStr":"3581585314538349","authorId":3581585314538349,"name":"AurulentL","avatar":"https://static.tigerbbs.com/4868228f6b994364c7acca908458c7ec","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":169624850,"type":1,"supId":4806878,"prevId":0,"content":"Comment Pls","text":"Comment Pls","html":"Comment Pls"},{"id":4806931,"gmtCreate":1623834316935,"gmtModify":1635316694278,"authorId":3580473686930895,"author":{"id":3580473686930895,"idStr":"3580473686930895","authorId":3580473686930895,"name":"Veldora","avatar":"https://static.tigerbbs.com/2c60768e017f3418615cd7dea3a291ec","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3581585314538349,"repliedAuthor":{"id":3581585314538349,"idStr":"3581585314538349","authorId":3581585314538349,"name":"AurulentL","avatar":"https://static.tigerbbs.com/4868228f6b994364c7acca908458c7ec","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":169624850,"type":1,"supId":4806878,"prevId":4806886,"content":"Commented","text":"Commented","html":"Commented"}],"langContent":"EN"},{"id":169628763,"gmtCreate":1623833886852,"gmtModify":1634027382977,"author":{"id":"3566081983681494","authorId":"3566081983681494","name":"HyperBaka","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3566081983681494","authorIdStr":"3566081983681494"},"htmlText":"A","listText":"A","text":"A","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/169628763","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806816,"gmtCreate":1623833911885,"gmtModify":1635316703924,"authorId":3567894781486535,"author":{"id":3567894781486535,"idStr":"3567894781486535","authorId":3567894781486535,"name":"megastonks","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":169628763,"type":1,"supId":0,"prevId":0,"content":"nice","text":"nice","html":"nice"}],"langContent":"EN"},{"id":169628593,"gmtCreate":1623833880912,"gmtModify":1634027383226,"author":{"id":"3562118563279867","authorId":"3562118563279867","name":"Desmond669","avatar":"https://static.tigerbbs.com/e2484115c94d3471cb46f20ea7598b4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3562118563279867","authorIdStr":"3562118563279867"},"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/169628593","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806819,"gmtCreate":1623833915134,"gmtModify":1635316703612,"authorId":3561620162335246,"author":{"id":3561620162335246,"idStr":"3561620162335246","authorId":3561620162335246,"name":"JZT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":169628593,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"}],"langContent":"EN"},{"id":169628951,"gmtCreate":1623833850973,"gmtModify":1634027383719,"author":{"id":"3567894781486535","authorId":"3567894781486535","name":"megastonks","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3567894781486535","authorIdStr":"3567894781486535"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/169628951","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806805,"gmtCreate":1623833888257,"gmtModify":1635316704784,"authorId":3561620162335246,"author":{"id":3561620162335246,"idStr":"3561620162335246","authorId":3561620162335246,"name":"JZT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":169628951,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"}],"langContent":"EN"},{"id":169621749,"gmtCreate":1623833839381,"gmtModify":1634027383963,"author":{"id":"3560481430779928","authorId":"3560481430779928","name":"Raymond杨","avatar":"https://static.tigerbbs.com/a0e904d9a1021ec74841e99e765cf608","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3560481430779928","authorIdStr":"3560481430779928"},"htmlText":"Nice kindly comment thank you","listText":"Nice kindly comment thank you","text":"Nice kindly comment thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/169621749","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806812,"gmtCreate":1623833903362,"gmtModify":1635316704144,"authorId":3561620162335246,"author":{"id":3561620162335246,"idStr":"3561620162335246","authorId":3561620162335246,"name":"JZT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":169621749,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"}],"langContent":"EN"},{"id":169621213,"gmtCreate":1623833836132,"gmtModify":1634027384310,"author":{"id":"3581750840520859","authorId":"3581750840520859","name":"bkohh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581750840520859","authorIdStr":"3581750840520859"},"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/169621213","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806848,"gmtCreate":1623834018198,"gmtModify":1635316701416,"authorId":3570536834617523,"author":{"id":3570536834617523,"idStr":"3570536834617523","authorId":3570536834617523,"name":"kenta","avatar":"https://static.tigerbbs.com/4593b44a03124dfaa74fc1d7d7ff0b35","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":169621213,"type":1,"supId":0,"prevId":0,"content":"<u>wow</u>","text":"<u>wow</u>","html":"<u>wow</u>"}],"langContent":"EN"},{"id":169621611,"gmtCreate":1623833830133,"gmtModify":1634027384433,"author":{"id":"3574937196457388","authorId":"3574937196457388","name":"Rayechia","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3574937196457388","authorIdStr":"3574937196457388"},"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/169621611","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806787,"gmtCreate":1623833848849,"gmtModify":1635316706038,"authorId":3581750840520859,"author":{"id":3581750840520859,"idStr":"3581750840520859","authorId":3581750840520859,"name":"bkohh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":169621611,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":169623800,"gmtCreate":1623833797600,"gmtModify":1634027385150,"author":{"id":"3549779044737399","authorId":"3549779044737399","name":"CollinNgu","avatar":"https://static.tigerbbs.com/3445861095aeb1d5cf3bf64b420c060c","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3549779044737399","authorIdStr":"3549779044737399"},"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/169623800","repostId":1150256789,"repostType":4,"repost":{"id":"1150256789","kind":"news","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<html><body><p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8   <a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\"><strong>benzinga</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4806780,"gmtCreate":1623833829235,"gmtModify":1635316706674,"authorId":3582190252904748,"author":{"id":3582190252904748,"idStr":"3582190252904748","authorId":3582190252904748,"name":"QQ23","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":169623800,"type":1,"supId":0,"prevId":0,"content":"<u>Yup</u>","text":"<u>Yup</u>","html":"<u>Yup</u>"},{"id":4806798,"gmtCreate":1623833868681,"gmtModify":1635316705405,"authorId":3569282887853056,"author":{"id":3569282887853056,"idStr":"3569282887853056","authorId":3569282887853056,"name":"Princessleo","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":169623800,"type":1,"supId":4806780,"prevId":0,"content":"Yup","text":"Yup","html":"Yup"},{"id":4806799,"gmtCreate":1623833871782,"gmtModify":1635316705297,"authorId":3574937196457388,"author":{"id":3574937196457388,"idStr":"3574937196457388","authorId":3574937196457388,"name":"Rayechia","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":169623800,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":4806916,"gmtCreate":1623834261395,"gmtModify":1635316695854,"authorId":3574320588413401,"author":{"id":3574320588413401,"idStr":"3574320588413401","authorId":3574320588413401,"name":"LW100","avatar":"https://static.tigerbbs.com/5b57af0729a9fd62bb8bac5304505b9d","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3569282887853056,"repliedAuthor":{"id":3569282887853056,"idStr":"3569282887853056","authorId":3569282887853056,"name":"Princessleo","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":169623800,"type":1,"supId":4806780,"prevId":4806798,"content":"<u>Comment</u>","text":"<u>Comment</u>","html":"<u>Comment</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":25,"commentSize":17,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}